Navigation Links
Terumo Americas Holding Acquires Onset Medical Corporation, a Leader in Innovative Sheath Technology Designed for Multiple, Minimally Invasive Clinical Applications

SOMERSET, N.J., Jan. 16, 2012 /PRNewswire/ -- Terumo Americas Holding, Inc. (TAH), a U.S. subsidiary of Japan's Terumo Corporation, one of the world's leading medical device manufacturers with $4 billion in sales and operations in more than 160 nations, today announced that it has acquired Onset Medical Corporation ("Onset"), an innovative medical device company located in Irvine, CA, that focuses on developing first-in-class access sheath technology designed for multiple, minimally invasive clinical applications in cardiology and urology.

Using its proprietary Controlled Deployment Technology (CDT) platform, Onset has developed the smallest sheath profiles with the largest internal diameters of any available access sheath to protect against unnecessary access site or arterial trauma for the patient. Onset's Associates will join with TAH subsidiary Terumo Medical Corporation as part of its Terumo Interventional Systems (TIS) business unit, where the CDT platform will complement TIS' complete product line of industry leading entry site management and lesion access technologies.

Terumo customers will have access to Onset's complete product lines.  The SoloPath™ Balloon Expandable Transfemoral and Transseptal Catheters' expandable and collapsable sheath technology allows TIS to enter the global structural heart and aneurysmal repair markets, providing an access platform for complex, large-bore procedures including Transcatheter Aortic Valve Implantation (TAVI), Thoracic Endovascular Aortic/Aneurysm Repair (TVAR) and Endovascular Aneurysm/Aortic Repair (EVAR).  The Pathway™ Balloon Expandable PCNL Sheath and Pathway™ Balloon Expandable Ureteral Access Sheath provide physicians with a one-step option for performing procedures such as Percutaneous Nephrolithotomy in the removal of large renal calculi (kidney stones).

"We welcome Onset to the Terumo family and look forward to providing our customers with current and future products based on the exciting CDT platform, which represents a tremendous complement to our overall value proposition as the leaders in entry site management and lesion access," said James Rushworth, Senior Vice President and General Manager, Terumo Medical Corporation and President, Onset Medical Corporation.  "CDT literally changes the way physicians enter the vascular system and manage the access site, while allowing them to achieve easier, safer access to the target lesion in a variety of clinical applications.  This strategic acquisition reinforces our commitment to pursuing unique technologies that meet the specialized needs of our customers and contribute to better outcomes for their patients."

As a global leader in vascular access management, TIS can effectively maximize the potential of the CDT-based platform when compared with competitors who do not specialize in entry site management.

"When Terumo approached us, it quickly became clear that they were the established leader in entry site management and the best company to commercialize our sheath technology on a global scale," said Joseph Bishop, Vice President and Chief Operating Officer, Onset Medical Corporation. "It is gratifying to know that our unique devices will immediately strengthen their core capability and will be featured prominently among other class-leading technologies that drive better patient outcomes."

For more information, contact Robert Murphy, The Storch-Murphy Group, 908.276.0777.    

Terumo Interventional Systems

Terumo Interventional Systems (TIS), a strategic business unit of Terumo Medical Corporation, directly markets a full line of guidewires, catheters, introducer sheaths, guiding sheaths and embolization products for use in a multitude of different interventional procedures. Interventional Radiologists, Interventional Neuroradiologists, Interventional Cardiologists, and Vascular Surgeons are among the medical professionals that depend upon TIS products to access and cross difficult-to-reach lesions, thereby allowing therapeutic intervention in previously unreachable vascular beds.

Terumo Medical Corporation

Founded in 1972 as a Terumo Corporation subsidiary, Terumo Medical Corporation (TMC) develops, manufactures, and markets high-quality medical devices used in a broad range of applications in numerous healthcare markets. TMC manufactures a broad portfolio of needles and syringes, entry-site management products, and a line of sterile connection devices used in hospitals and blood banks worldwide.

Terumo Corporation

Tokyo-based Terumo Corporation is one of the world's leading medical device manufacturers with $4.0 billion in sales and operations in more than 160 nations.  Founded in 1921, the company develops, manufactures, and distributes world-class medical devices including products for use in cardiothoracic surgery, interventional procedures, and transfusion medicine; the company also manufactures a broad array of syringe and hypodermic needle products for hospital and physician office use.  Terumo contributes to society by providing valued products and services to the healthcare market and by responding to the needs of healthcare providers and the people they serve.  Terumo Corporation's shares are listed on the first section of the Tokyo Stock Exchange (No. 4543, Reuters symbol <4543.T>, or Bloomberg 4543:  JP) and is a component of the Nikkei 225, Japan's leading stock index.

SOURCE Terumo Americas Holding, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Terumo Heart to Announce Results of European Clinical Trial of DuraHeart(TM) LVAS at European Association of Cardiothoracic Surgeons Meeting in September
2. Terumo Heart Reports Summary of DuraHeart(TM) LVAS Clinical Trial Results
3. Terumo Heart Summarizes Results of DuraHeart(TM) LVAS Implants
4. Terumo Heart Obtains IRB Approval from the University of Michigan to Initiate DuraHeart(TM) Left Ventricular Assist System U.S. Pivotal Trial
5. Terumo Heart, Inc. Reports Clinical Progress in the DuraHeart(TM) U.S. Pivotal Trial as NewYork-Presbyterian Hospital/Columbia University Medical Center Implants First Patient
6. Terumo Heart, Inc. Reaches Clinical Milestone as the 100th Patient Worldwide Receives the DuraHeart(TM) Left Ventricular Assist System
7. Terumo Cardiovascular Systems Initiates U.S. Clinical Trial for Anaconda(TM) AAA Stent Graft System
8. Terumo to Sponsor Presentations on Key Issues in Cardiac and Vascular Surgery at Society of Thoracic Surgeons Annual Meeting
9. Terumo To Simultaneously Evaluate Misago Self-Expanding Stent System in the United States and Japan
10. VirtuoSaph® Plus Endoscopic Vessel Harvesting System from Terumo Continues the Advancement of the Minimally Invasive Technique for Coronary and Peripheral Artery Bypass Grafting
11. Terumo Cardiovascular Systems Reaches Agreement on Terms of Consent Decree With FDA Regarding Quality System Improvements
Post Your Comments:
(Date:11/29/2015)... 2015 CIVCO Medical Solutions will demonstrate ... Radiological Society of North America ... November 29 – December 4, 2015. The ... customers unrivaled versatility, enhanced user experience and deliver ... --> --> ...
(Date:11/27/2015)... Nov. 27, 2015  Lannett Company, Inc. (NYSE: ... completed the acquisition of Kremers Urban Pharmaceuticals Inc. ... global biopharmaceuticals company UCB S.A. (Euronext: UCB). ... has acquired KU from UCB for total consideration ... including a customary working capital adjustment, a deduction ...
(Date:11/26/2015)... Carolina , 26 november 2015 /PRNewswire/ ... (AAIPharma/CML) kondigt de geplande investering aan van ... van de laboratoria en het mondiale hoofdkantoor ... De uitbreiding zal resulteren in extra kantoorruimte ... voldaan aan de groeiende behoeften van de ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... According to an article published ... Association meeting in Washington D.C. revolved around the fact that proper dental care, both ... talk stressed the link between periodontal disease (more commonly referred to as gum disease) ...
(Date:11/27/2015)... PA (PRWEB) , ... November 27, 2015 , ... ... be a safe and convenient way to dispense prescription medications at home, so ... and effective way to monitor and dispense prescription medications. In doing so, it ...
(Date:11/27/2015)... ... ... MPWH, the No.1 Herpes-only dating community in the world, revealed that over 50% of its ... 3.7 billion people under the age of 50 – or 67% of the population - ... estimates of HSV-1 infection . , "The data shocks us highly!" said Michelle Li, ...
(Date:11/27/2015)... ... November 27, 2015 , ... Keeping ... platform for mental health and wellness consultation, has collaborated with a leading web-based ... the knowledge gap experienced by parents and bring advice from parenting experts within ...
(Date:11/27/2015)... , ... November 27, 2015 , ... ... center software Q-Suite, announces the incorporation of Asterisk 11 LTS (Long Term Support) ... supported Asterisk 11 LTS brings Q-Suite 5.10 up-to-date with a version of Asterisk ...
Breaking Medicine News(10 mins):